AIM ImmunoTech Inc. (AIM): Price and Financial Metrics
AIM Price/Volume Stats
| Current price | $0.47 | 52-week high | $0.75 |
| Prev. close | $0.48 | 52-week low | $0.32 |
| Day low | $0.47 | Volume | 78,100 |
| Day high | $0.50 | Avg. volume | 212,136 |
| 50-day MA | $0.43 | Dividend yield | N/A |
| 200-day MA | $0.50 | Market Cap | 23.20M |
AIM Stock Price Chart Interactive Chart >
AIM ImmunoTech Inc. (AIM) Company Bio
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Latest AIM News From Around the Web
Below are the latest news stories about AIM IMMUNOTECH INC that investors may wish to consider to help them evaluate AIM as an investment opportunity.
AIM ImmunoTech Provides Update Regarding Annual MeetingOCALA, Fla., November 28, 2023--AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the Company will convene its upcoming 2023 Annual Meeting of Stockholders (the "2023 Annual Meeting") as planned on December 1, 2023, and will then adjourn proceedings, without conducting any other business, until December 29, 2023. The purpose of the adjournment is to provide the Delaware Court of Chancery (the "Court") with sufficient time to issue a ruling with respect to the |
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. PatentsExtends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 11,813,279 and 11,813,281 for Ampligen® titled “Compositions for cancer therapy and methods,” and “Methods for improving exercise |
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID ConditionsNo severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the last subject has completed treatment in the Company’s Phase 2 study evaluating Ampligen® as a potential therapeutic for people with the Post-COVID condition of fatigue (“AMP-518”). AIM Chief Executive Officer Thomas K. Equels commented, “With dosing now complete, our AMP-518 focus t |
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed ChangeTed D. Kellner, Todd Deutsch and Robert L. Chioini (collectively, the "Kellner Group") today issue the following statement in connection with their efforts to bring accountability to the entrenched, incumbent Board of Directors of AIM Immunotech Inc. (NYSE American: AIM) and create value for stockholders. The Kellner Group is convinced that they have the experience to make AIM successful and that an immediate change in directors on the AIM board at this year's annual meeting is absolutely necess |
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will host conference call and webcast today, November 15th at 8:30 AM ET OCALA, Fla., Nov. 15, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter 2023 and provided a business update. As previously announced, the Com |
AIM Price Returns
| 1-mo | 23.36% |
| 3-mo | 11.88% |
| 6-mo | 7.50% |
| 1-year | -7.57% |
| 3-year | -77.83% |
| 5-year | -92.43% |
| YTD | 6.84% |
| 2023 | 41.04% |
| 2022 | -66.10% |
| 2021 | -48.60% |
| 2020 | 229.04% |
| 2019 | -93.17% |
Loading social stream, please wait...